أعرض في EDS

The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease

التفاصيل البيبلوغرافية
العنوان:	The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease
المؤلفون:	Decramer, Marc L, Hanania, Nicola A, Lötvall, Jan, 1956, Yawn, Barbara P
المصدر:	International journal of chronic obstructive pulmonary disease. 8:53-64
مصطلحات موضوعية:	Respiratory Medicine and Allergy, Lungmedicin och allergi, Adrenergic beta-2 Receptor Agonists, adverse effects, Albuterol, analogs & derivatives, Blood Glucose, analysis, Cough, chemically induced, Ethanolamines, Headache, Humans, Indans, Nasopharyngitis, Potassium, blood, Pulmonary Disease, Chronic Obstructive, drug therapy, Quinolones, Respiratory Tract Infections, Spasm, Tachycardia, Tremor
الوصف:	Inhaled long-acting bronchodilators are the mainstay of pharmacotherapy for chronic obstructive pulmonary disease (COPD). Both the twice-daily long-acting β(2)-adrenoceptor agonists (LABAs) salmeterol and formoterol and the once-daily LABA indacaterol are indicated for use in COPD. This review examines current evidence for the safety of LABAs in COPD, focusing on their effect on exacerbations and deaths.
الوصول الحر:	https://gup.ub.gu.se/publication/182506Test
قاعدة البيانات:	SwePub

الوصف
تدمد:	11782005
DOI:	10.2147/COPD.S39018